Ibsa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for IBSA, and when can generic versions of IBSA drugs launch?
IBSA has five approved drugs.
There are seven US patents protecting IBSA drugs.
There are thirty-two patent family members on IBSA drugs in sixteen countries and one supplementary protection certificate in one country.
Drugs and US Patents for Ibsa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ibsa | TIROSINT | levothyroxine sodium | CAPSULE;ORAL | 021924-004 | Oct 13, 2006 | RX | Yes | No | 7,723,390 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Ibsa | TIROSINT-SOL | levothyroxine sodium | SOLUTION;ORAL | 206977-009 | Dec 15, 2016 | RX | Yes | No | 11,096,913 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Ibsa | TIROSINT-SOL | levothyroxine sodium | SOLUTION;ORAL | 206977-014 | Jan 13, 2021 | RX | Yes | No | 10,537,538 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Ibsa Inst Bio | LICART | diclofenac epolamine | SYSTEM;TOPICAL | 206976-001 | Dec 19, 2018 | RX | Yes | Yes | 11,351,133 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ibsa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ibsa | TIROSINT | levothyroxine sodium | CAPSULE;ORAL | 021924-004 | Oct 13, 2006 | 7,691,411 | ⤷ Sign Up |
Ibsa | FLECTOR | diclofenac epolamine | SYSTEM;TOPICAL | 021234-001 | Jan 31, 2007 | 5,607,690 | ⤷ Sign Up |
Ibsa | TIROSINT | levothyroxine sodium | CAPSULE;ORAL | 021924-013 | Aug 1, 2007 | 7,691,411 | ⤷ Sign Up |
Ibsa | TIROSINT | levothyroxine sodium | CAPSULE;ORAL | 021924-008 | Oct 2, 2009 | 7,691,411 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for IBSA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Topical Patch | 1.3% | ➤ Subscribe | 2015-06-26 |
International Patents for Ibsa Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Poland | 3528847 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2020178074 | ⤷ Sign Up |
Portugal | 3930703 | ⤷ Sign Up |
Japan | 4851064 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ibsa Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1291021 | 132012902104794 | Italy | ⤷ Sign Up | PRODUCT NAME: LEVOTIROXINA SODICA(ALIASINT); AUTHORISATION NUMBER(S) AND DATE(S): RVG 106848; 106850-106860, 20110407;DA 041528011/M A 041528365/M, 20120808 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.